Antimicrobial activity of three different endodontic sealers on the enterococcus faecalis and lactobacillus (in vitro)

Introduction: Growth and proliferation of the remaining microorganisms within the root canals may destroy the surrounding tissue of the root and leads to periapical lesion. Consequently, the complete elimination of microorganisms from the root canal is an important goal of endodontic therapy. Endodontic sealers do not provide complete seal in root canal system, and micro spaces have always remained between the material and canal walls that lead to penetration of these spaces, so, an antibacterial activity is essential for sealers. The aim of the present study was the in vitro evaluation of antimicrobial activity of the three endodontic sealers on two microorganisms. Methods: To study the effect of each sealer; AH26, MTA Fillapex and ADseal on Enterococcus Faecalis and Lactobacillus bacteria 10 samples were considered. In this experimental study, 60 plates were exposed to bacteria and 10 plates were considered for control group. Sealer antibacterial effect on bacterial growth was studied after 48 hours. Firstly, the freshly prepared sealers were poured inside the micro tube and diffused in the wall of the micro tube. Then solution of nutrient broth was poured into a micro tube and the determined volume of solution of bacterial suspension was added into a microtube and was kept 24 hours in the incubator to grow the bacteria. Then, it was poured in the plates of blood agar and cultured after 24 hours and then the colonies grown on the plates were counted in sufficient light. The data were analyzed with MANOVA statistical test and SPSS Version 18. Results: Most bacteria grew in the plates of ADseal sealer and MTA fillapex sealer with means of 5113.00CFU and 3077.00CFU respectively, while the lowest number of bacteria grew in the plates of AH26 sealer with a mean of 1345.15CFU. Conclusions: Most antibacterial activities of each enterococcus faecalis and lactobacillus bacteria sample was for AH26 sealer and MTA fillapex sealer. The lowest antibacterial activity was for ADseal sealer

National burden of rheumatoid arthritis in Canada, 1990–2019: findings from the Global Burden of Disease Study 2019 – a GBD collaborator-led study

Objective The objectives of this study were: (1) to describe burden of rheumatoid arthritis (RA) and trends from 1990 to 2019 using the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) data, (2) to describe age and sex differences in RA and (3) to compare Canada’s RA burden to that of other countries.Methods Disease burden indicators included prevalence, mortality, years of life lost (YLLs), years lived with disability (YLDs) and disability-adjusted life-years (DALYs). GBD estimated fatal and non-fatal outcomes using published literature, survey data and health insurance claims. Data were analysed by Bayesian meta-regression, cause of death ensemble model and other statistical methods. DALYs for Canada were compared with DALYs of countries with similarly high Socio-Demographic Index values.Results In Canada, the RA prevalence rate increased by 27% between 1990 and 2019, mortality rate decreased by 27%, YLL rate decreased by 30%, YLD increased by 27% and DALY rate increased by 13%, all age standardised. The decline in RA mortality and YLL rates was especially pronounced after 2002. The disease burden was higher in females for all indicators, and DALY rates were higher among older age groups, peaking at age 75–79 years. Prevalence and DALYs were higher in Canada compared with global rates.Conclusion Trends in RA burden indicators over time and differences by age and sex have important implications for Canadian policy-makers, researchers and care providers. Early identification and management of RA in women may help reduce the overall burden of RA in Canada

Health trends in Canada 1990-2019:An analysis for the Global Burden of Disease Study

Monitoring trends in key population health indicators is important for informing health policies. The aim of this study was to examine population health trends in Canada over the past 30 years in relation to other countries. We used data on disability-adjusted life years (DALYs), years of life lost (YLL), years lived with disability, life expectancy (LE), and child mortality for Canada and other countries between 1990 and 2019 provided by the Global Burden of Disease Study. Life expectancy, age-standardized YLL, and age-standardized DALYs all improved in Canada between 1990 and 2019, although the rate of improvement has leveled off since 2011. The top five causes of all-age DALYs in Canada in 2019 were neoplasms, cardiovascular diseases, musculoskeletal disorders, neurological disorders, and mental disorders. The greatest increases in all-age DALYs since 1990 were observed for substance use, diabetes and chronic kidney disease, and sense organ disorders. Age-standardized DALYs declined for most conditions, except for substance use, diabetes and chronic kidney disease, and musculoskeletal disorders, which increased by 94.6%, 14.6%, and 7.3% respectively since 1990. Canada's world ranking for age-standardized DALYs declined from 9th place in 1990 to 24th in 2019. Canadians are healthier today than in 1990, but progress has slowed in Canada in recent years in comparison with other high-income countries. The growing burden of substance abuse, diabetes/chronic kidney disease, and musculoskeletal diseases will require continued action to improve population health. [Abstract copyright: © 2024. The Author(s) under exclusive license to The Canadian Public Health Association.